Drug Profile

DF 8101

Alternative Names: DF-8101

Latest Information Update: 24 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

18 Nov 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to November 2022 (Dragonfly Therapeutics pipeline, November 2022)
19 Mar 2020 Dragonfly Therapeutics and Merck & Co expand strategic collaboration to discover, develop and commercialise immunotherapies for Immunological disorders and infections
01 Oct 2018 Dragonfly Therapeutics and Merck & Co enter into a strategic collaboration agreement to develop immunotherapies for Solid tumours

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com